Group 1 - The core viewpoint of the articles highlights the performance and market position of Shenzhen New Industry Biomedical Engineering Co., Ltd. in the medical device sector, particularly in the in vitro diagnostics field [1][2] - As of August 1, the company's stock closed at 54.25 yuan, down 2.29%, with a rolling PE ratio of 23.17 times and a total market capitalization of 42.625 billion yuan [1] - The average PE ratio for the medical device industry is 53.65 times, with a median of 37.22 times, placing the company at the 50th position within the industry [1][2] Group 2 - The company reported a net profit of 438 million yuan for Q1 2025, reflecting a year-on-year increase of 2.65%, with a sales gross margin of 68.01% [1] - The company has received notable accolades, including the "National Brand Gold Award" for medical equipment in 2024, indicating strong customer satisfaction and service recognition, particularly in tertiary hospitals [1] - As of March 31, 2025, the number of shareholders increased to 19,269, with an average holding value of 352,800 yuan and an average shareholding of 27,600 shares [1]

证券代码：300832 证券简称：新产业 公告编号：2025-058 深圳市新产业生物医学工程股份有限公司 关于公司获得发明专利证书的公告 专利权人：深圳市新产业生物医学工程股份有限公司 发明人：王逸贤、郑晓林、何国耀、刘振华、熊英超、张婷婷、陈慕潇、马娟娟、盛雪晴 专利申请日：2023年12月25日 授权公告日：2025年07月15日 上述专利保护技术为公司自主研发，本发明应用于全自动核酸检测分析系统 Molecision R8，提供了一种试剂配制装置及具有其的核酸检测一体机，通过使用 同一加注部和同一抓取机构，即可在试剂配制装置中进行提取试剂和扩增试剂的 配制以及提取板和扩增板两种耗材的转移，从而实现全自动核酸检测分析仪器的 小型化设计需求。 本次取得的发明专利不会对公司目前的经营状况产生重大影响，但有利于完 善公司知识产权体系，进一步提升公司软实力。 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 深圳市新产业生物医学工程股份有限公司（以下简称"公司"）于近日收到 日本特许厅颁发的1项《发明专利证书》，现将本次取得的发明专利具体情况公 告如下： 发明名称 ...

Core Viewpoint - China's commercial space industry is entering a fast development phase, with high-frequency and low-cost commercial launches becoming a reality. The integration of various sectors, from rocket launches to satellite manufacturing, is forming a complete industrial chain [1] Group 1: Industry Development - The integration of technological innovation and industrial innovation is crucial for the growth of the commercial space sector [1] - The Central Political Bureau meeting on July 30 emphasized the need for technological innovation to lead the development of new productive forces and to cultivate internationally competitive emerging pillar industries [1] - The government aims to promote the safe and healthy development of emerging industries such as commercial space, low-altitude economy, and deep-sea technology [1] Group 2: Market Potential - China possesses rich market demand and application scenarios, providing a broad prospect for the development of emerging industries [1] - The commercial space market is expected to exceed 2.5 trillion yuan by 2025 [1] - With strong innovation drivers, emerging industries like commercial space are anticipated to reach greater heights and distances in the future [1]

哈尔滨电碳厂如今的生产设备。 本报记者 郭晓龙摄 7月30日召开的中共中央政治局会议强调，坚持以科技创新引领新质生产力发展，加快培育具有国际竞 争力的新兴支柱产业，推动科技创新和产业创新深度融合发展。 "传统产业改造升级，也能发展新质生产力。"一块电碳、一颗金刚石、一根弹簧……一个个脱胎于传统 产业的新技术、新材料、新工艺，为新兴产业和未来产业带来宝贵机遇，也为自身开拓更为广阔的应用 场景。 本版今起推出"新产业里的传统力量"系列报道，讲述几家传统企业转型发展的故事。 ——编 者 松花江畔，黑龙江哈尔滨电碳厂有限责任公司的生产车间里，巨大的设备低鸣，一块块看似不起眼的乌 黑色碳石墨材料在精密的流水线上流转、成型。 "转型的阵痛很剧烈，部分老客户流失、收入一度减少。"马庆春坦言，"但我们没气馁，当时厂里挂着 一句十分提气的标语，'宁可少赚三年，也要赢在未来'。" 持续的研发投入，终于带来丰厚产出。"把钱花在刀刃上！"马庆春的桌上，放着一沓研发报告——核电 主泵水导石墨轴承等的成功开发，填补了国内空白。订单随之而来，今年一季度，哈碳公司新增订单 6152万元，比去年同期增长21.1％，企业又加力投入300万元研发 ...

Core Insights - China's commercial space industry is entering a rapid development phase, with high-frequency and low-cost commercial launches becoming a reality [1] - The integration of technological innovation and industrial innovation is crucial for the growth of the commercial space sector [1] - The market demand and policy guidance are fostering the growth of emerging industries, with a projected market size of over 2.5 trillion yuan by 2025 for the commercial space sector [1] Group 1 - The commercial space industry in China is developing a complete industrial chain, encompassing various sectors from rocket launches to satellite manufacturing [1] - The Central Political Bureau meeting emphasized the importance of technological innovation in leading the development of new productive forces and fostering internationally competitive emerging pillar industries [1] - The government work report this year highlighted the need to promote the safe and healthy development of emerging industries such as commercial space, low-altitude economy, and deep-sea technology [1] Group 2 - The integration of resources is essential for the scientific allocation of industrial elements, alongside a long-term commitment to breakthrough key core technologies [1] - The rich market demand and application scenarios in China provide a broad prospect for the development of emerging industries [1] - With strong innovation drivers, the commercial space industry and other emerging sectors are expected to reach greater heights and distances in the future [1]

Core Viewpoint - The Central Political Bureau of the Communist Party of China emphasizes the importance of technological innovation in leading the development of new productive forces and fostering emerging industries with international competitiveness [1] Group 1: Company Transformation - Harbin Electric Carbon Factory, established during the First Five-Year Plan, faced significant losses and market challenges, particularly in the low-end product sector [3][4] - The company decided to eliminate most low-end product lines and focus on high-end markets such as high-speed rail, wind power, and nuclear power, despite initial revenue declines and customer losses [4] - The factory's commitment to research and development has led to successful innovations, including the development of graphite bearings for nuclear power pumps, filling a domestic gap [4][5] Group 2: Research and Development - The company has a strong emphasis on R&D, with over 20% of its workforce being young researchers, including many from the post-80s and post-90s generations [5][6] - Continuous training and mentorship from experienced technicians are provided to enhance the R&D capabilities of younger engineers [5][6] - The company encourages a culture of exploration and learning from failures, allowing for rapid industrialization of successful products [6]

Core Points - The Guangzhou Development Zone and Huangpu District launched measures to empower high-quality industrial development through financial services and a "zero rent" pilot program for industrial space [1][3] - Approximately 150,000 square meters will be allocated for the "zero rent" pilot program, aimed at reducing operational costs for enterprises [1][3] - The policy targets strategic emerging industries such as intelligent connected vehicles, biomedicine, low-altitude economy, artificial intelligence, and new displays [3][4] Group 1 - The "zero rent" policy offers significant cost savings for technology startups, with potential savings in the millions [6] - The policy is designed to lower the entry barriers and costs for small and micro enterprises, facilitating their innovation and growth [4][6] - The initiative includes support for award-winning projects from innovation and entrepreneurship competitions, providing corresponding rent exemptions [3][4] Group 2 - The implementation details are being finalized by state-owned enterprises, with an expected rollout in mid-August [6] - The program aims to create a supportive ecosystem by offering value-added services such as financial, legal, and entrepreneurial guidance [8][10] - The Guangzhou Development Zone is exploring diverse rental models to enhance market competitiveness and attract quality projects [8][10] Group 3 - Specific pilot projects under the "zero rent" initiative include various industrial parks and centers focusing on emerging industries [11][12][13] - The initiative is part of a broader strategy to foster a healthy cycle of operation, value addition, and reinvestment in new projects [10]

Group 1 - The core viewpoint of the articles highlights the performance and market position of Shenzhen New Industry Biomedical Engineering Co., Ltd. in the medical device sector, particularly in the in vitro diagnostics field [1] - As of July 31, the company's stock closed at 55.52 yuan, down 3.24%, with a rolling PE ratio of 23.71 times and a total market capitalization of 43.623 billion yuan [1] - The average PE ratio for the medical device industry is 54.89 times, with a median of 37.06 times, placing the company at the 49th position within the industry [1][2] - The company has 48 institutional holders, all of which are funds, holding a total of 33.4155 million shares valued at 1.895 billion yuan [1] - The company specializes in the research, production, sales, and customer service of in vitro diagnostic products, with its main products being diagnostic instruments and reagents [1] - The company received the "National Brand Gold Award" for medical equipment in 2024 and ranked first in various customer satisfaction metrics in tertiary hospitals, indicating strong customer recognition of its services [1] - In the latest quarterly report for Q1 2025, the company achieved a revenue of 1.125 billion yuan, a year-on-year increase of 10.12%, and a net profit of 438 million yuan, a year-on-year increase of 2.65%, with a gross profit margin of 68.01% [1] Group 2 - The company's PE (TTM) is 23.71, while the static PE is 23.86, and the price-to-book ratio is 4.84 [2] - Comparatively, the industry average PE (TTM) is 54.89, and the median is 37.06, indicating that the company is significantly below the industry average [2] - Other companies in the industry have varying PE ratios, with the lowest being 10.93 for Jiuan Medical and the highest being 19.94 for Antu Biology, showcasing a wide range of valuations within the sector [2]

Group 1: Event Overview - The investor relations activity took place from July 2 to July 24, 2025 [2] - The event was held at the New Industry Biomedical Building, located at 23 Jinxiu East Road, Kengzi Street, Pingshan District, Shenzhen [2] - A total of 10 institutions participated, with 12 attendees [2] Group 2: Participants - Participating institutions included GIC Private Limited, Tiger Pacific Capital LP, and Huaneng Guicheng Trust Co., Ltd. [4] - Other notable participants were Jiangxi Peter Mingqi Private Fund Management Co., Ltd. and Shanghai Chongyang Investment Management Co., Ltd. [4] Group 3: Company Representatives - The event featured company representatives such as Zhang Lei, the Deputy General Manager and Board Secretary [2] - Investor relations were managed by Lu Yuning, the head of investor relations [2] Group 4: Content Summary - No new major interactive content was introduced beyond previously disclosed investor relations activities [2]

天眼查商业履历信息显示，深圳市新产业生物医学工程股份有限公司，成立于1995年，位于深圳市，是 一家以从事专用设备制造业为主的企业。企业注册资本78571.8785万人民币，实缴资本10000万人民 币。公司法定代表人为饶微。 金融界消息 截至2025年7月31日收盘，新产业（300832）报收于55.52元，下跌3.24%，换手率1.24%， 成交量8.41万手，成交金额4.71亿元。 资金流向方面，今日主力资金净流入2617.62万元，占比成交额5.56%。其中，超大单净流入1090.70万 元、占成交额2.31%，大单净流入1526.92万元、占成交额3.24%，中单净流出流入1620.92万元、占成交 额3.44%，小单净流出4238.54万元、占成交额9.0%。 新产业最新一期业绩显示，截至2025一季报，公司营业总收入11.25亿元、同比增长10.12%，归属净利 润4.38亿元，同比增长2.65%，扣非净利润4.17亿元，同比增长4.39%，流动比率8.417、速动比率 6.542、资产负债率7.46%。 通过天眼查大数据分析，深圳市新产业生物医学工程股份有限公司共对外投资了6家企业，参与招投标 ...